Exploring 4^th generation EGFR inhibitors: A review of clinical outcomes and structural binding insights

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Epidermal growth factor receptor (EGFR) is a key driver in non-small cell lung cancer (NSCLC) development and progression.
• EGFR mutations necessitate targeted therapies like tyrosine kinase inhibitors (TKIs), with resistance emerging as a significant clinical challenge.
• The EGFR-C797S mutation represents a critical resistance mechanism against existing EGFR TKIs.

Purpose of the Study:

• To review novel EGFR TKIs developed in the last five years for NSCLC treatment.
• To analyze the clinical outcomes and structure-activity relationships of these emerging inhibitors.
• To explore binding mechanisms and the role of artificial intelligence in advancing EGFR inhibitor design.

Main Methods:

• Comprehensive literature review of EGFR TKIs reported in the past five years.
• Analysis of clinical outcomes, structure-activity relationships, and binding modes of identified inhibitors.
• Exploration of artificial intelligence (AI) applications, including recursive neural networks and reinforcement learning, in EGFR inhibitor discovery.

Main Results:

• Identification and summary of various synthetic EGFR TKIs designed to overcome resistance mutations.
• Detailed structure-activity relationship analysis and binding mode insights for novel compounds.
• Demonstration of AI's potential in accelerating drug screening, predicting mutations, and generating novel EGFR inhibitors.

Conclusions:

• Recent advancements in EGFR TKI development offer promising therapeutic strategies against NSCLC, particularly those with resistance mutations.
• Understanding binding interactions is crucial for rational drug design and overcoming treatment resistance.
• AI-driven approaches are transforming the landscape of targeted cancer therapy by enhancing the efficiency and innovation in drug discovery.